New Delhi: Active Pharmaceutical Material Manufacturer Glenmark Sciences’ Rs 1,514 Crore ($ 203.65 million) The initial public offering is now open to subscribe.
The problem is, with the ribbon price of Rs 695-720 per share, will conclude on July 29.
Glenmark’s life science on Monday said it had caused Rs 454 Crore from an investor anchor before the sale of initial shares.
The company has decided to allocate 63,06,660 equity shares up to 19 anchor investors at Rs 720 per share, aggregate to RS 454 Crore, according to regulations.
HSBC Global Investment Funds, Global Government Pension Funds, Oaktree Emerging Markets LP Equity, Copthall Mauritius Investment Ltd -Odi, Societe Generale-Odi, Kuber India Funds and Reliance Company are among the anchor investors.
Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals, is a leading developer and manufacturer of certain active pharmaceutical materials, non-commoditical active pharmacy (API) in the chronic therapy area, including cardiovascular disease, central nervous system disease, pain management and diabetes.
The company also produces and sells fire for gastro-intestinal disorders, anti-infection and other therapeutic regions.
Half of the total problems have been reserved for eligible institutional buyers, 35 percent for retail investors, and the remaining 15 percent for non-institutional investors.
Goldman Sachs (India) Securities Private Limited, SBI Capital Markets, Mahindra Capital Company Box, Bofa Securities India Ltd, Dam Capital Advisors Ltd and Bob Capital Markets is the main manager for this problem.
The company’s equity stock will be registered with BSE and NSE.
(With input from agency)